Sex Differences in the Genetic Causes of Dilated Cardiomyopathy
Mangino M. et al, (2025), Journal of the American College of Cardiology, 86, 400 - 403
Regulatory T cells attenuate chronic inflammation and cardiac fibrosis in hypertrophic cardiomyopathy
Wang Y-J. et al, (2025), Science Translational Medicine, 17
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.
Saberi S. et al, (2025), JACC. Heart failure, 13
An ALPK3 truncation variant causing autosomal dominant hypertrophic cardiomyopathy is partially rescued by mavacamten.
Leinhos L. et al, (2025), Sci Rep, 15
Developing p21-activated kinase 1 (PAK1) activators to treat hypertrophic cardiomyopathy (HCM)
He Y. et al, (2024), EUROPEAN HEART JOURNAL, 45
Genetic therapies for cardiomyopathy: survey of attitudes of the patient community for the CureHeart project
Ormondroyd E. et al, (2024), EUROPEAN JOURNAL OF HUMAN GENETICS, 32, 1837 - 1838
Genetic therapies for cardiomyopathy: survey of attitudes of the patient community for the CureHeart project
Ormondroyd E. et al, (2024), EUROPEAN JOURNAL OF HUMAN GENETICS, 32, 1837 - 1838
Non-obstructive hypertrophic cardiomyopathy exhibit subclinical abnormalities in systolic and diastolic ventricular kinetic energy and systolic haemodynamic forces on 4D flow CMR
Pola K. et al, (2023), EUROPEAN HEART JOURNAL, 44
Subclinical Flow Inefficiencies in Non-Obstructive Hypertrophic Cardiomyopathy Subgroups Revealed by 4D Flow Cardiovascular Magnetic Resonance
Pola K. et al, (2023), CIRCULATION, 148